37US
Cryo-EM structure of human Fibroblast Activation Protein alpha in complex with H4 VNAR
Summary for 37US
| Entry DOI | 10.2210/pdb37us/pdb |
| EMDB information | 78501 |
| Descriptor | Fibroblast activation protein alpha, H4 variable new antigen receptor-human IgG Fc fusion protein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total) |
| Functional Keywords | fibroblast activation protein alpha, fap, variable new antigen receptor, vnar, hydrolase |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 4 |
| Total formula weight | 254554.82 |
| Authors | Broadberry, R.L.,Ott, K.L.,Lake, E.W.,Hemme, C.A.,LeBeau, A.M.,Grant, T. (deposition date: 2026-08-06, release date: 2026-11-04) |
| Primary citation | Broadberry, R.L.,Ott, K.L.,Lake, E.W.,Ravi, T.,Hemme, C.A.,Chi, S.,West, J.L.,Gunaratne, G.S.,Ong, I.M.,LeBeau, A.M.,Grant, T. A shark variable new antigen receptor recognizes an occluded epitope of fibroblast activation protein. Biorxiv, 2026 Cited by PubMed Abstract: Variable new antigen receptors (VNARs) are the smallest naturally occurring antibody binding domains. Their size allows VNARs to access sterically restricted epitopes that are inaccessible to conventional antibodies. We recently identified a suite of VNARs that target fibroblast activation protein (FAP), a stromal serine protease indicative of extracellular matrix remodeling. The presence of FAP on the surface of cancer-associated fibroblasts (CAFs) that promote immunosuppression has made FAP a compelling therapeutic target for cancer therapy. Although antibodies targeting FAP have been developed, there is a paucity of information on how biologics engage FAP. Here, we used single-particle cryogenic electron microscopy (cryo-EM) to compare FAP recognition of three antibody architectures: a shark-derived VNAR, variable heavy (V) and light domains (V) of a humanized Immunoglobulin G (IgG), and a camelid-derived VHH. The humanized V-V domains and camelid VHH both target a solvent-exposed β-propeller domain, whereas the VNAR binds a highly conserved, topologically recessed epitope at the FAP dimer interface. Radical-footprinting mass spectrometry (MS) further mapped two additional immune-derived VNARs to distinct FAP surfaces outside the shared β-propeller epitope. These findings demonstrate how unique VNAR architecture can expand access to underexplored FAP surfaces and establish a structural framework for rational multiepitope targeting strategies. PubMed: 42845595DOI: 10.64898/2026.08.11.744296 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.01 Å) |
Structure validation
Download full validation report






